Navigation Links
Clinical trial will test new HIV/AIDS vaccine
Date:4/3/2008

BOSTON A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Womens Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.

This study will involve 48 healthy volunteers who will receive either two or three immunizations and who will be followed to assess the safety and immunogenicity of the vaccine, explains Lindsey R. Baden, MD, Assistant Professor of Medicine at BWH and Harvard Medical School and Protocol Chair for the study.

The vaccine consists of a replication-incompetent, recombinant adenovirus serotype 26 (rAd26) vector encoding an HIV-1 envelope gene.

The rAd26 vaccine vector was selected for its particularly low seroprevalence in human populations and for its potent immunogenicity and protective efficacy in preclinical studies, explains Dan H. Barouch, MD, PhD, Associate Professor of Medicine at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School and Principal Investigator of the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program that developed the vaccine. This program is sponsored by the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Manufactured by the Dutch biotechnology company Crucell Holland BV, the rAd26 vaccine is the first HIV-1 vaccine candidate to emerge from the IPCAVD initiative, which brings together investigators from academia and industry in an effort to accelerate the development of promising HIV/AIDS vaccine candidates. The novel strategy used in developing this vaccine enables researchers to circumvent preexisting immunity to the adenovirus serotype 5, the virus responsible for the common cold, which has recently shown limitations as an HIV-1 vaccine vector.

The rAd26 vector does not regularly occur in the human population and human antibodies to this vector are rare, explains Jaap Goudsmit, Chief Scientific Officer at Crucell. The rAd26 vector therefore is efficacious in eliciting good T and B cell responses.

AIDS remains one of the worlds most devastating health problems, with an estimated 33.2 million people living with HIV/AIDS and 2.5 million new infections reported in 2007 alone.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... services and financial consultations to communities throughout the greater DC region, is inaugurating ... the goal of rescuing local animals and training them to be companions for ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning services to communities in east Texas, is launching a regional ... Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... The ... communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to ... husband. , In early June of this year, Christina and her children returned from ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over ... in bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for ... aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/11/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it will release its ... host a conference call at 9:00am ET. The Company ... results and its strategy and outlook for the remainder ... Erez Raphael , Chief Executive Officer, and Zvi ...
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
Breaking Medicine Technology: